Swedbank AB Grows Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Swedbank AB increased its holdings in Thermo Fisher Scientific Inc. by 6.3%, acquiring an additional 100,282 shares, bringing its total to approximately 1.68 million shares, valued at around $682.8 million.
• Multiple institutional investors, including KMG Fiduciary Partners and Signal Advisors Wealth, have also increased their stakes in Thermo Fisher, reflecting significant interest in the company with 89.23% of the stock owned by institutional investors.
• Analyst ratings for Thermo Fisher are generally positive, with a consensus rating of "Moderate Buy" and varied price targets, including a notable upgrade from Scotiabank to a price target of $590.00.

Swedbank AB increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,684,058 shares of the medical research company's stock after purchasing an additional 100,282 shares during the quarter. Thermo Fisher Scientific accounts for 0.8% of Swedbank AB's investment portfolio, making the stock its 21st largest position. Swedbank AB owned approximately 0.45% of Thermo Fisher Scientific worth $682,818,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after buying an additional 230,382 shares in the last quarter. Amundi grew its stake in Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after acquiring an additional 329,974 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent research reports. HSBC reiterated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $1.08 during midday trading on Friday, hitting $480.02. The stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. The firm has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a P/E/G ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The stock has a 50-day simple moving average of $472.01 and a 200 day simple moving average of $450.02. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the business earned $5.37 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.